CJC-1295 / Ipamorelin Nasal Spray

CJC-1295, Ipamorelin — nasal spray format

This listing supplies the compound as a pre-mixed nasal spray rather than a lyophilized vial, so no reconstitution step is required before use in a laboratory workflow. Intranasal delivery is studied as a non-injectable route that avoids first-pass hepatic metabolism; the published literature summarised below was generated across a range of administration routes, and route is one of the variables recorded in the reported-amounts table. Comparisons between routes are not equivalence claims — absorption differs by formulation and is documented per product, not inferred.

Because this nasal spray is supplied pre-prepared, the reconstitution arithmetic that applies to our lyophilized CJC-1295, Ipamorelin vials does not apply here: there is no diluent volume to choose and no concentration to derive. Store as labelled on the product, and consult the lot-matched Certificate of Analysis for the material you receive rather than generalising from a different format of the same compound.

Technical overview

CJC-1295 / Ipamorelin Nasal Spray combines CJC-1295 and Ipamorelin. Each component is summarised below as it appears in the published literature.

CJC-1295

Long-acting GHRH analog

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), engineered to extend stimulation of pituitary GH release relative to native GHRH(1-29). The best-known research form includes a Drug Affinity Complex (DAC) moiety that enables covalent albumin binding after injection, markedly prolonging half-life and supporting multi-day GH/IGF-1 elevations in published human pharmacokinetic studies.

Investigators value CJC-1295 as a tool compound for GH-axis pharmacology: it helped demonstrate that prolonged GHRH-receptor stimulation can raise GH and IGF-1 while still preserving pulsatile GH patterns in healthy adults. A shorter-acting related sequence (often discussed as CJC-1295 without DAC / Mod GRF 1-29) is used when labs want brief pulses instead of multi-day exposure.

Research-grade CJC-1295 is Research Use Only. It is not FDA-approved for human use and is not for human consumption. Reported ranges differ sharply between DAC and non-DAC forms; the figures below are literature references, not recommendations.

Ipamorelin

Growth hormone secretagogue (ghrelin receptor agonist)

Ipamorelin is a pentapeptide growth hormone secretagogue that stimulates the ghrelin receptor (GHS-R1a). Researchers value it because early work suggested strong GH release with comparatively little stimulation of ACTH and cortisol at doses that still moved GH—an important selectivity contrast versus older GHRP scaffolds.

Human pharmacokinetic-pharmacodynamic modeling and multiple preclinical growth studies established the core profile: a short circulating half-life, a discrete GH pulse, and dose-responsive somatotropic signaling. Ipamorelin remains a frequent reference compound in GH-axis, body-composition, and secretagogue-combination research.

In research-supply contexts it is almost always handled as a lyophilized peptide for subcutaneous investigation. Content on this page is educational and research-use-only; ipamorelin is not an FDA-approved therapeutic product.

Mechanism of action

CJC-1295

CJC-1295 acts at the GHRH receptor on anterior-pituitary somatotrophs. Receptor activation increases cAMP and triggers GH secretion. In the DAC-bearing form, reactive conjugation to circulating albumin slows clearance, producing sustained GHRH-receptor tone. Downstream, elevated GH drives hepatic and local IGF-1 production. Studies report that physiologic GH pulsatility can persist even under continuous analog stimulation.

Ipamorelin

Ipamorelin binds the growth hormone secretagogue receptor GHS-R1a, the same receptor activated by ghrelin. Receptor activation on pituitary somatotrophs promotes GH vesicle release. Because the peptide is relatively selective, experimental comparisons often highlight GH elevation with muted collateral HPA-axis activation versus earlier GHRPs. The short half-life produces a pulse-like GH exposure rather than a flat, prolonged elevation.

Research applications

• GH/IGF-1 axis pharmacology
• long-acting GHRH analog design
• pituitary somatotroph signaling
• body-composition biomarker research
• albumin-bioconjugate peptide PK
• growth hormone axis research
• ghrelin receptor pharmacology
• body composition and recovery models
• bone growth preclinical research
• secretagogue combination studies

Fields of active investigation, not claims. Investigation is not proof.

Endocrine pharmacologists, peptide-engineering groups, and GH-axis biology labs are the main audience. Anti-doping analytics groups have also published detection methods because GHRH analogs appear on prohibited-substance lists in sport contexts.

Endocrinology labs, sports-medicine research groups, and peptide pharmacology teams use ipamorelin when they need a selective GH secretagogue comparator. It also appears in protocol papers exploring GHRH-analogue plus GHRP co-administration. The audience is research personnel, not patients seeking treatment advice.

Amounts reported in the literature

What published research and laboratory protocols document. These describe what was studied — they are not instructions, recommendations, or a protocol for use.

Handling and storage

CJC-1295

Store lyophilized peptide refrigerated or frozen, away from light and humidity. After reconstitution, refrigerate and aliquot if the protocol requires repeated sampling over multiple days.

Ipamorelin

Keep lyophilized vials cold, dry, and protected from light. After reconstitution with bacteriostatic water, refrigerate and avoid repeated warm-cold cycling; many labs aliquot to limit handling stress.

Notes on combined research

CJC-1295

Research protocols frequently examine CJC-1295 together with a ghrelin-mimetic GHRP or GHS-R agonist such as ipamorelin or hexarelin because GHRH and ghrelin pathways can converge on GH release through complementary receptors. DAC versus non-DAC choice is usually the first experimental branch point.

Ipamorelin

Ipamorelin is frequently discussed alongside GHRH analogues such as CJC-1295 (with or without DAC) or sermorelin because the two classes hit complementary nodes of GH release. Research stacks aim to amplify pulse amplitude while preserving physiologic timing. Literature comparisons sometimes include other GHRPs (GHRP-2, GHRP-6) when ranking selectivity and side-effect profiles.

Analytical specifications

Identity and purity are documented per lot on the Certificate of Analysis for the material you receive. Lot, manufacture and expiry are stamped on the base of the vial or bottle.

Frequently asked questions

CJC-1295: What is CJC-1295 peptide dosage in published research?
For CJC-1295 with DAC, Teichman et al. studied about 30-60 mcg/kg subcutaneously in healthy adults. Non-DAC analogs are commonly discussed around 100-300 mcg per exposure because they clear much faster.

Ipamorelin: What is the dosage for ipamorelin?
Laboratory and secondary research summaries most often cite roughly 200–300 mcg per subcutaneous administration, sometimes repeated up to two or three times daily because of the short half-life. Published human PK work used IV mcg/kg infusions rather than a single universal SC chart.

CJC-1295: What is the difference between CJC-1295 with DAC and without DAC?
DAC enables albumin binding and multi-day activity. Without DAC, the peptide behaves like a short-acting GHRH analog and is typically studied with more frequent administration.

Ipamorelin: How much BAC water for ipamorelin?
A practical research reconstitution is 2–3 mL bacteriostatic water in a 5 mg or 10 mg vial. Example: 5 mg + 2.5 mL yields 200 mcg per 10 units on a U-100 syringe. Confirm arithmetic against your exact vial label.

CJC-1295: Does CJC-1295 destroy normal GH pulses?
Published work reported that pulsatile GH secretion can persist during continuous stimulation by long-acting CJC-1295, with higher mean and trough GH levels.

Ipamorelin: Ipamorelin dosage per day?
Daily totals in informal research discussions often land near 200–900 mcg/day when split across one to three injections. Those figures are commonly cited reference ranges, not individualized medical directions.

CJC-1295: Is CJC-1295 FDA-approved?
No. Research-grade CJC-1295 is RUO laboratory material and is not an approved drug product for human use.

Ipamorelin: Ipamorelin dosage chart?
Charts usually convert vial strength and diluent volume into mcg-per-tick-mark on an insulin syringe, then list once-, twice-, or thrice-daily pulse schedules. Use them only as research math aids.

References

Every reference below resolves to an indexed paper. We would rather cite less and cite accurately.

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
• Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
• Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.
• Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.
• Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.
• Ipamorelin, the first selective growth hormone secretagogue.
• Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.
• Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.

Research use only

For laboratory and research purposes only. Not for human consumption, veterinary use, or medical applications. This product is not a drug, food, supplement or cosmetic, is not approved by the FDA, and is not intended to diagnose, treat, cure or prevent any disease. This page summarises published scientific literature; it is not medical advice and not a recommendation to use this compound. All handling must be performed by qualified personnel in a controlled laboratory environment.